全部商品分类
下载产品说明书 下载SDS
用小程序，查商品更便捷
收藏
对比
咨询Scientific Data
View LargerRecombinant Human BCAT2 (Catalog # 9537-BA) is measured by its ability to convert leucine and alpha-ketoglutarate to alpha-ketoisocaproate and glutamate.
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
9537-BA
| Formulation | Supplied as a 0.2 μm filtered solution in Tris, NaCl, DTT and Glycerol. |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Recombinant Human BCAT2 Protein, CF Summary
Product Specifications
Ala28-Val392
with an N-terminal Met and 6-His tag
Analysis
Background: BCAT2
Branched-chain-amino-acid aminotransferases (BCATs) are enzymes that catalyze the first reaction in the catabolism of the essential branched-chain amino acids leucine, isoleucine, and valine to their respective keto-acids while concurrently producing glutamate. BCATs belong to the class-IV pyridoxal-phosphate-dependent (PLP-dependent) aminotransferase family of enzymes (1). There are two BCAT isozymes in humans and mammals, a mitochondrial form known as BCATm or BCAT2 and a cytosolic form known as BCATc or BCAT1 that share 55% sequence identity. In humans and rodents, BCATc is almost exclusively present in the nervous system (2,3) while BCATm is constitutively expressed in most tissues and is generally thought to be important in body nitrogen metabolism (1,2). The 41 kDa human BCATm exists as an active homodimer and has a unique CXXC active site near the dimerization domain (4). Knockouts display decreased adiposity and obesity through alterations of leucine-dependent mTOR signaling making it a potential therapeutic target for obesity (5). BCATm can be regulated by oxidative stress, interfering with its ability to interact with protein disulfide isomerase (6). BCATm overexpression in the brain is detectable in Alzheimers disease and dementia (7,8) suggesting it plays an important role in glutamate toxicity, a key pathogenic feature of these diseases.
- Hutson, S. (2001) Prog. Nucleic. Acid Res. Mol. Biol. 70:175.
- Suryawan, A. et al. (1998) Am. J. Clin. Nutr. 68:72.
- Hall, T.R. et al. (1993) J. Biol. Chem. 268:3092.
- Yennawar, N. H. (2006) J. Biol. Chem. 281:39660. (BCATm)
- She, P. et al. (2007) Cell Metab. 6:181.
- El Hindy, M. et al. (2014) Antioxid. Redox Signal 20:2497.
- Ashby, E.L. et al. (2017) Neurochem. Res. 42:306.
- Hull, J. et al. (2015) J. Alzheimers Dis. 45:891.
参考图片
Recombinant Human BCAT2 (Catalog # 9537-BA) is measured byits ability to convert leucine and alpha-ketoglutarate to alpha-ketoisocaproateand glutamate.